Compass Pathways Plc ADR
Geschlossen
12.49 -1.26
Übersicht
Veränderung der Aktienkurses
24h
Min
12.33
Max
13.48
Einkommen | 185M 91M |
|---|---|
EPS | -0.3 |
Angestellte | 156 |
EBITDA | 139M 93M |
Empfehlungen | Starkes Kaufsignal |
|---|---|
12-Monats-Prognose | +85.77% upside |
Nächstes Ergebnis | 30. Juli 2026 |
|---|
Marktkapitalisierung | 428M 1.7B |
|---|---|
Vorheriger Eröffnungskurs | 13.75 |
Vorheriger Schlusskurs | 12.49 |
Compass Pathways Plc ADR Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
